Genovis AB (GENO) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Genovis AB has changed its score on 26 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at SEK 24.57 MM
INTEREST(9M) At SEK 0.29 MM has Grown at 122.48%
NET PROFIT(HY) At SEK 8.57 MM has Grown at -41.01%

With ROE of 11.29%, it has a very expensive valuation with a 5.88 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 1,391 Million (Small Cap)

P/E

52.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.58

Return on Equity

8.04%

Price to Book

5.28

Revenue and Profits:

Net Sales:

29 Million

(Quarterly Results - Jun 2025)

Net Profit:

5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.31%

6 Months

-21.35%

1 Year

-16.7%

2 Years

-58.85%

3 Years

-51.83%

4 Years

-69.06%

5 Years

-30.56%

Genovis AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

16.65%

EBIT Growth (5y)

85.46%

EBIT to Interest (avg)

26.63

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.74

Sales to Capital Employed (avg)

0.63

Tax Ratio

35.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

46.73%

ROE (avg)

18.20%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.88

EV to EBIT

48.58

EV to EBITDA

34.84

EV to Capital Employed

17.01

EV to Sales

10.15

PEG Ratio

0.93

Dividend Yield

ROCE (Latest)

35.02%

ROE (Latest)

11.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -10.53% vs 15.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 45.71% vs -23.91% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28.90",
          "val2": "32.30",
          "chgp": "-10.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.20",
          "val2": "11.60",
          "chgp": "-37.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.10",
          "val2": "3.50",
          "chgp": "45.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "160.30%",
          "val2": "281.50%",
          "chgp": "-12.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.57% vs 54.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.50% vs 449.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "130.40",
          "val2": "158.20",
          "chgp": "-17.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.30",
          "val2": "63.70",
          "chgp": "-38.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "32.90",
          "val2": "61.50",
          "chgp": "-46.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "221.20%",
          "val2": "341.30%",
          "chgp": "-12.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

28.90

32.30

-10.53%

Operating Profit (PBDIT) excl Other Income

7.20

11.60

-37.93%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

Consolidate Net Profit

5.10

3.50

45.71%

Operating Profit Margin (Excl OI)

160.30%

281.50%

-12.12%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -10.53% vs 15.77% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 45.71% vs -23.91% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

130.40

158.20

-17.57%

Operating Profit (PBDIT) excl Other Income

39.30

63.70

-38.30%

Interest

4.00

0.00

Exceptional Items

0.00

Consolidate Net Profit

32.90

61.50

-46.50%

Operating Profit Margin (Excl OI)

221.20%

341.30%

-12.01%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -17.57% vs 54.49% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.50% vs 449.11% in Dec 2023

All Annual Results

Company CV

About Genovis AB

Genovis AB

Pharmaceuticals & Biotechnology

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Company Coordinates

Company Details

Medicon Village, Scheelevagen 2 , LUND None : 223 63

Tel: 46 46 101230

https://www.genovis.com/

Registrar Details